Business
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
- Vaccination yields broad neutralizing antibody responses against original strain and Beta, Gamma and Delta variants - Durable response demonstrated against
About this update from Soligenix, Inc.
[{"type":"text","content":"- Vaccination yields broad neutralizing antibody responses against original strain and Beta, Gamma and Delta variants\n - Durable response demonstrated against original strain and all variants for several months after vaccination\n - Stronger neutralizing antibodies observed after infection, unlike the unvaccinated, naturally infected animals\n\n\n\n PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The article, titled \"Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1,\" has been posted as an accelerated preprint on bioRxiv (available here). The manuscript is part of the ongoing collaboration with Axel Lehrer, PhD, Associate Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawaiʻi at Mānoa (UHM). Development continues under a non-dilutive $1.5M Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) awarded to Soligenix in December 2020. \n\"This technology platform has previously demonstrated an encouraging ability to generate vaccines that are stable at ambient temperature, potentially avoiding the need for refrigerated or frozen storage and distribution,\" said Jerome Kim, MD, Director General of the International Vaccine Institute. \"The encouraging development of a broadly neutralizing and efficacious subunit vaccine specifically for SARS-CoV-2, including the variants of concern, using the same heat stable technology platform offers greater promise for achieving worldwide vaccination in the current pandemic.\"\n\"We continue to advance our work using our vaccine platform, consisting of a robust protein manufacturing process and a thermostabilizing formulation, using the Soligenix ThermoVax® process and the CoVaccine HT™ adjuvant. T...